Lates News

According to the Daily Economic News, on November 19th, the Pacific released a research report giving Si Tai Li (603520.SH) a "buy" rating. The main reasons for the rating include: 1) as a leading integrated iodine contrast agent "API + formulation" company, its internationalization strategy is steadily advancing; 2) the expansion of raw material pharmaceutical capacity is gearing up for growth, with multiple factors resonating to improve profitability; 3) the breakthrough of formulation production capacity bottleneck, driving growth domestically and overseas.